| ABSTRACT Objective：Our study focused on the clinical efficacy of amoxicillin clavulanic potassium acid combined with
azithromycin for the treatment of community-acquired pneumonia (CAP). Methods：145 CAP patients who were admittied during
January, 2010 -January 2012 were selected The patients were divided into two groups using a random number table, including treatment
group (73 cases) and control group (72 cases). The treatment group received amoxicillin clavulanic potassium acid and azithromycin
treatment, control group was applicated only by amoxicillin clavulanic potassium acid. Both groups were treated for 7 ~ 14 days. The
clinical efficacy were compared after treatment.Results： (1) In the treatment group, the amounts of cured, effective and invalid patients
were 43 cases (58.9%), 16 cases (21.9%), 8 cases (11.0%), 6 cases (8.2%) respectively, and they were 20 cases (27.8 %), 26 cases
(36.1%), 14 cases (19.4%), 12 cases (16.7%) in the control group . The difference between the two groups was statistically significant (P
<0.05). (2) In the treatment group, gastrointestinal reactions, local pain induced by intravenous infusion, and rash occurred in 6 cases
(8.2%), 7 cases (9.6%) and 3 cases (4.1%), the total adverse reaction rate was 21.9%(16 cases). However, in the control group they were
five cases (6.9%), 6 cases (8.3%), 3 cases (4.2%), 14 cases (19.4%). The adverse reaction rates were not statistically significant between
two groops(P>0.05). Conclusion：Amoxicillin clavulanic potassium combined with azithromycin treatment has better curative efficacy to
CAP. |
